Skip to main content

Table 1 The functions of m6A methyltransferases in drug and radiotherapy resistance

From: N6-methyladenosine methyltransferases: functions, regulation, and clinical potential

Therapy type

Drug name

Cancer

Regulator

Regulation

Target

References

Chemo-therapy

Cisplatin

Seminoma

METTL3

PR

TFAP2C

[92]

Gastric cancer

METTL3

PR

ARHGAP5

[93]

NSCLC

METTL3

ES

FSP1

[94]

NKTCL

WTAP

PR

DUSP6

[95]

Nasopharyngeal carcinoma

METTL3

PR

TRIM11

[43]

Oxaliplatin

Colorectal cancer

METTL3

PR

P53/Sec62

[96]

Taxol

Breast cancer

METTL3

PR

ERRγ

[98]

Doxorubicin (adriamycin)

Breast cancer

METTL3

PR

pri-microRNA-221-3p

[100]

Anthracycline

Breast cancer

METTL3

PR

ABCB1

[98]

Targeted therapy

Everolimus

Gastric tumors

METTL3

ES

pri-miR-17–92

[53]

Crizotinib

NSCLC

METTL3/WTAP

PR

c-MET

[108]

Gefitinib

NSCLC

METTL3

PR

METTL3-mediated Autophagy

[110]

Lung Adenocarcinoma

METTL3

PR

c-MET

[111]

Sorafenib

HCC

METTL14

PR

HNF3γ

[112]

HCC

METTL3/14

PR

circRNA-SORE

[42]

HCC

METTL3

ES

FOXO3

[74]

Immuno therapy

Anti-PD-1

Melanoma

METTL3 (macrophages)

PR

SPRED2

[57]

Colorectal carcinoma/Melanoma

METTL3/14

PR

Stat1/Irf1

[117]

Radio-therapy

γ-irradiation

Glioblastoma

METTL3

PR

SOX2

[76]

X-ray Irradiation

Hypopharyngeal Squamous cell carcinoma

METTL3

PR

circCUX1

[119]

  1. NSCLC non-small cell lung carcinoma, NKTCL nasal-type natural killer/T-cell lymphoma, HCC hepatocellular carcinoma, PR Promote resistance, ES Enhance sensitivity